Concord Drugs Ltd

Concord Drugs Limited: Closure of Trading Window from 01 October 2026 till 48 hours after the announcement/declaration of the un-audited financial results (standalone & consolidated) for the quarter and year ending 30 September 2026

AGM & AR Access

• AGM scheduled for 30 September 2026 at 09:30 IST via VC/OAVM.
• Annual Report for FY 2025-26 being sent electronically to registered email IDs.
• Shareholders without registered emails will access the AR via the provided web link.
• Web path to AR: concorddrugs.in/annual-reports/ Investors > Annual Reports.
• Shareholders should update email addresses with their DP to ensure timely communications.

Book closure & AGM details

• Book closure from 24 September 2026 to 30 September 2026 (inclusive).
• Purpose: for the 31st Annual General Meeting of Concord Drugs Limited.
• Record date: 23 September 2026 to determine voting eligibility.
• AGM date and time: 30 September 2026 at 09:30 A.M. via VC/OAVM.
• Security affected: Equity shares.

Financial performance

• Standalone revenue rose to ₹7,584.86 lakhs, up ~105% YoY.
• Standalone PAT ₹103.74 lakhs, up from ₹29.57 lakhs.
• Standalone PBT ₹144.86 lakhs.
• Standalone EPS ₹0.93 per share.
• Consolidated revenue ₹7,873.68 lakhs.
• Consolidated PAT ₹105.50 lakhs.
• Consolidated EPS ₹0.95 per share.
• Dividend for FY2025-26 not declared.
• Standalone CFO ₹-622.39 lakhs; Consolidated CFO ₹-574.92 lakhs.
• Consolidated revenue grew ~74% YoY.

Capital raise & capital base

• Preferential issue: 31.75 lakh equity shares and 20.25 lakh warrants.
• Issue price ₹36.30 per share; premium ₹26.30 per share.
• Total proceeds ₹18.876 crore from preferential issue.
• Authorized capital increased to ₹15.50 crore from ₹11.00 crore.
• Paid-up capital after issue ₹13.175 crore.

Capital structure & liquidity

• Debt-Equity: Standalone 0.48x; Consolidated 0.54x.
• Current Ratio: Standalone 2.74x; Consolidated 2.53x.
• Consolidated earnings per share improved to ₹0.95.
• Overall liquidity supported by capital raise and strong operating profitability.

Dividends & shareholder returns

• No dividend declared for the financial year 2025-26.

Governance & board changes

• Board met eight times in FY2025-26.
• Satyam Reddy Gopidi appointed Additional Independent Director on 8 Sep 2025.
• S. Nagavenkata Hareesh Kumar Solleti re-appointed Independent Director (2026–2031).
• Sumeela Kasu re-appointed Independent Director (2027–2032).
• M/s Pundarikashyam & Associates re-appointed Statutory Auditors for five years.

Related party transactions

• Material RPT with Proton Remedies, Cortex Laboratories, Seelam, Continental Pellets.
• Maximum transaction value ₹15 crore per related party for FY2026-27.
• Transactions are in ordinary course and at arm's length.
• RPTs reviewed and approved by Audit Committee/Board; disclosed in Form AOC-2.

Audit, controls & compliance

• Internal controls found adequate; no material weaknesses reported.
• Secretarial Audit by PSK & Associates; delays in Reg 76 filing flagged; SOP fine paid.
• MD/CFO certification attached; independent director declarations obtained.
• Corporate Governance report and related policies updated on company website.

Subsidiaries & group

• Proton Remedies Private Limited is a wholly owned subsidiary.
• Consolidated financial statements include Proton Remedies' results.

Outlook & risks

• Global pharma outlook positive; long-term growth supported by innovation.
• Indian pharma market expected to grow around 7-9% in FY2025-26.
• Risks include pricing pressures, regulatory changes, and FX volatility.

agm details

• AGM date/time/mode: 30 September 2026 at 09:30 AM via VC/OAVM.
• Book closure: 23 September 2026 to 30 September 2026.

resolutions put to vote

• Ordinary: adopt standalone and consolidated financial statements.
• Ordinary: re-appoint S. Nagi Reddy as director by rotation.
• Ordinary: re-appoint statutory auditors for five years; remuneration ₹4,00,000 per annum.
• Ordinary: approve related party transactions for 2026-27; maximum ₹15 crore; arm's length.
• Ordinary: ratify remuneration of cost auditors for 2026-27; ₹1,00,000.
• Special: re-appoint Independent Director Hareesh Solleti for second five-year term.
• Special: re-appoint Independent Director Sumeela Kasu for second five-year term.

voting and dividend

• Voting results: not disclosed in the filing.
• Dividend: no dividend proposed for FY2025-26.

director changes

• Additional Independent Director Satyam Reddy Gopidi appointed 08/09/2025; regularized 30/09/2025.
• Independent Director K. Ramachandra Reddy ceased on 14/02/2026.

auditors

• Statutory auditors: M/s Pundarikashyam & Associates; second term five years post-AGM; remuneration ₹4,00,000 p.a.

material related party transactions

• Related parties: Proton Remedies; Cortex Laboratories; Seelam Laboratories; Continental Pellets Pharma.
• Nature: sale of products; purchase of raw materials; job work.
• Maximum value: ₹15 crore for FY2026-27; arm's length.
• Share of turnover: about 19.04% of consolidated turnover.

other material approvals

• Increase in authorised share capital to ₹15.50 crore; approved 31 Jul 2025.
• Preferential allotment: 31,75,000 equity shares and 20,25,000 warrants.
• Trading/listing approvals obtained in April 2026.
• Board/committee reconstitution after cessation of K. Ramachandra Reddy on 14 Feb 2026.

AGM Notice & Reporting

• Approved Notice and Annual Report for the 31st AGM on 30 September 2026 via VC.

Book Closure & Voting Cut-off

• Approved book closure to 30 Sep 2026 and cut-off date 23 Sep 2026 for remote e-voting.

Financial Statements

• Approved Audited standalone and consolidated financial statements for FY ended 31 March 2026.

Directors – Rotation & Independents

• Approved re-appointment of Mr. S. Nagi Reddy as Chairman & MD, retiring by rotation.
• Re-appointment of S. Nagavenkata Hareesh Kumar Solleti as Independent Director for a second five-year term, subject to approval.
• Re-appointment of Ms. Sumeela Kasu as Independent Director for a second five-year term, subject to approval.

Auditors

• Approved re-appointment of M/s Pundarikashyam and Associates as Statutory Auditors for five years; remuneration 34,00,000 per annum.
• Approved ratification of remuneration payable to Cost Auditor M/s KJU & Associates for 2026-27.

Related Party Transactions

• Approved seeking members' approval for material related party transactions for FY 2026-27, in ordinary course and arm's length.

Financial results and audit notes

• Board approved unaudited standalone and consolidated financial results for quarter ended 30 June 2026.
• Board noted Limited Review Reports issued by the statutory auditors.
• Results to be published in newspapers as per SEBI LODR requirements.
• Results available on Concord Drugs website and BSE website.

Meeting Details

• Board meeting scheduled for 10 August 2026 at the company's Registered Office.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter ended June 30, 2026.

Other Notes

• Trading window closed for designated persons and their immediate relatives until 48 hours after results declaration.